Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
| Revenue (TTM) | $56.69B |
| Gross Profit (TTM) | $42.51B |
| EBITDA | $23.10B |
| Operating Margin | 34.60% |
| Return on Equity | 30.30% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $29.64 |
| Book Value | $21.86 |
| Price-to-Book | 6.90 |
| Price-to-Sales (TTM) | 5.09 |
| EV/Revenue | 5.77 |
| EV/EBITDA | 14.57 |
| Quarterly Earnings Growth (YoY) | -17.00% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $1.90B |
| Float | $1.86B |
| % Insiders | 0.01% |
| % Institutions | 7.27% |
Volatility is currently contracting
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthcare which was planning a generic rival.
Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine, the performance of its oncology franchise was remarkably strong. So, sales of Pluvicto, a medication used to treat PSMA-positive metastatic castration-resistant prostate cancer, were $651 million in Q2, up 43.4% year-on-year.
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning.
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto.
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stock futures are rising after three straight days of declines for major indexes; chip stocks are leading the rebound as volatility in the AI trade persists; several big-name companies reported earnings this morning ahead of Big Tech results tomorrow; Nebius shares are surging on news Nvidia as increased its stake in the Dutch AI infrastructure company; and SpaceX shares are rising after closing lower for the seventh consecutive sessions. Here's what you need to know today.
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected for the company in the second half of the year.
Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVS and any ticker you trade — then tracks every position and per-strategy win rate.
